Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study.

Satoshi Ida,Katunori Betou,Yuki Ishihara,Akihiro Uchida,Ryutaro Kaneko,Hiroka Takahashi,Kou Monguchi,Ryoko Fujiwara,Kanako Imataka,Chiaki Kobayashi,Kazuya Murata

doi:10.1186/s12933-016-0468-4

Satoshi Ida, Katunori Betou + Show 9 more

Open Access

https://doi.org/10.1186/s12933-016-0468-4

Copy DOI

Journal: Cardiovascular diabetology	Publication Date: Nov 4, 2016
Citations: 63	License type: cc-by

Affiliation: Ise Red Cross Hospital

Abstract

BackgroundTrelagliptin, an oral DPP-4 inhibitor, which is administered once per week and characterized by a long half-life in blood. The effects of trelagliptin on vascular endothelial functions have not been clarified to date. The objective of the present study was to examine the effects of trelagliptin on vascular endothelial functions in patients with type 2 diabetes mellitus (DM) using flow-mediated dilatation (FMD), adiponectin, and asymmetric dimethylarginine (ADMA) as evaluation indicators.MethodsThis study was a preliminary single-arm prospective pilot study. The subjects of this study were type 2 DM patients aged 20–74 years, who visited our outpatient department. The patients were treated with trelagliptin, and their FMD, adiponectin, and ADMA levels were measured at baseline and at 12 weeks after initial treatment to determine the changes during the study period.ResultsA total of 27 patients, excluding three dropouts, were included in the population for analysis. Trelagliptin treatment showed no significant changes in FMD (2.42 ± 2.7% at baseline vs. 2.66 ± 3.8% post-treatment, P = 0.785) and ADMA (0.41 ± 0.0 µg/mL at baseline vs. 0.40 ± 0.0 µg/mL post-treatment, P = 0.402). Trelagliptin treatment resulted in a significant increase of serum adiponectin level (7.72 ± 6.9 µg/mL at baseline vs. 8.82 ± 8.3 µg/mL post-treatment, P < 0.002).ConclusionsIn this pilot study, trelagliptin treatment showed no significant changes in FMD. On the other hand, it was believed that trelagliptin treatment may increase serum adiponectin level. Trial Registration http://www.umin.ac.jp (Trial ID UMIN000018311)

Highlights

Trelagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, which is administered once per week and characterized by a long half-life in blood
At baseline and 12 weeks following the initial treatment with trelagliptin (50–100 mg once per week), we evaluated the flow-mediated dilatation (FMD), adiponectin level, asymmetric dimethylarginine (ADMA) level, mean carotid intima media thickness (CIMT), mean brachial-ankle pulse wave velocity, fasting blood glucose level, hemoglobin A1c (HbA1c) level, serum lipid level, body weight, and body mass index (BMI)
Trelagliptin treatment showed no significant changes in FMD (2.42 ± 2.7% at baseline vs. 2.66 ± 3.8% post-treatment, P = 0.785) and ADMA (0.41 ± 0.0 μg/mL at baseline vs. 0.40 ± 0.0 μg/mL post-treatment, P = 0.402)

Summary

Introduction

Trelagliptin, an oral DPP-4 inhibitor, which is administered once per week and characterized by a long half-life in blood. The objective of the present study was to examine the effects of trelagliptin on vascular endothelial functions in patients with type 2 diabetes mellitus (DM) using flow-mediated dilatation (FMD), adiponectin, and asymmetric dimethylarginine (ADMA) as evaluation indicators. The incidences of type 2 diabetes mellitus (DM) have been increasing during recent years and are associated with increasing incidences of cardiovascular diseases, which comprise a serious potential outcome [1]. Trelagliptin is considered as an oral DPP-4 inhibitor administered once per week and characterized by a long half-life in the blood.

Objectives

Methods

Results

Conclusion